VIMIZIM (BioMarin Pharmaceutical Inc.)


Welcome to the PulseAid listing for the VIMIZIM drug offered from BioMarin Pharmaceutical Inc.. This alpha-Glucosidases [Chemical/Ingredient],Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: BioMarin Pharmaceutical Inc.
NON-PROPRIETARY NAME: elosulfase alfa
SUBSTANCE NAME: ELOSULFASE ALFA
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: alpha-Glucosidases [Chemical/Ingredient],Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, SOLUTION, CONCENTRATE
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2014-02-14
END MARKETING DATE: 0000-00-00


VIMIZIM HUMAN PRESCRIPTION DRUG Details:

Item DescriptionVIMIZIM from BioMarin Pharmaceutical Inc.
LABELER NAME: BioMarin Pharmaceutical Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 5(mg/5mL)
START MARKETING DATE: 2014-02-14
END MARKETING DATE: 0000-00-00
PRODUCT ID: 68135-100_0e11ad00-28de-4c01-baf4-500c4f4ad080
PRODUCT NDC: 68135-100
APPLICATION NUMBER: BLA125460

Other ELOSULFASE ALFA Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
BioMarin Pharmaceutical Inc.VIMIZIM